Newton Fund - Accelerating cost-effective development of improved treatments for COPD and other respirtory diseases in China

该项目侧重于为使人衰弱的呼吸系统疾病，特别是慢性阻塞性肺病提供具有成本效益的保健服务。目前，中国40岁以上人口中有1 / 12患有慢性阻塞性肺病。由于耐药，患者对目前的治疗往往反应不佳。我们的创新方法将用一种廉价、简单、有效的干粉吸入器（DPI）装置克服这一问题，该装置包含两种现有药物的新组合。创新的超临界流体（SCF）技术独特地提供了制备所需的高规格药物粉末的能力。该项目的基本知识要求将通过连接领先的中心-英国Crystepharma和帝国理工学院- SIMM和中国上海复旦张江生物制药有限公司来满足。结果将包括新的DPI的“首次人体”研究，并在中国建立一个临床前测试中心和SCF生产设施。除COPD产品外，还将开发一系列改进的药物/设备患者吸入产品，旨在经济有效地治疗中国其他广泛存在的呼吸系统疾病挑战。

This project focuses on cost effective health care provision for debilitating respiratory diseases, and especially chronic obstructive pulmonary disease (COPD). COPD currently affects 1 in 12 of the Chinese population over 40. Frequently patients respond poorly to current treatment due to drug resistance. Our innovative approach will overcome this issue with an inexpensive, simple, efficacious, dry powder inhaler (DPI) device containing a novel combination of two existing drugs. Innovative supercritical fluid (SCF) technology uniquely provides the ability to prepare the high specification drug powders required. Essential knowledge requirements for the project will be met by bridging leading centres - Crystepharma and Imperial College in the UK with SIMM and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. in China. Outcomes will include ‘first in man’ studies for the new DPI, and creating a preclinical testing centre and SCF manufacturing facilities in China. In addition to the COPD product, a range of improved drug/device patient inhaled products will be developed aimed to treat cost effectively other widespread respiratory disease challenges in China.